D. Medical CEO interviewed on Bloomberg TV

Efri Argaman, CEO of D. Medical Industries (NASDAQ, TASE:DMED), was interviewed today by Sara Eisen on Bloomberg Television’s “InsideTrack.” Mr. Argaman discussed a host of topics, ranging from the state of the U.S. diabetes market, regulatory oversight and D. Medical’s sales strategy in the U.S. Instead of setting up a direct and costly U.S. sales [...]

D. Medical inks fifth U.S. distributor of diabetic infusion sets

D. Medical Industries (NASDAQ, TASE:DMED) has signed a non-exclusive agreement with Solara Medical Supplies for the distribution of its Spring Universal Infusion Sets in the U.S. The accord has an initial term of two years, beginning with Solara’s initial order, and then automatically renewed for one-year periods. “We have been very pleased by the strong [...]

D. Medical expands U.S. distribution of infusion sets

D. Medical Industries (NASDAQ, TASE:DMED) has signed a non-exclusive agreement with Better Living Now, expanding the distribution of its Spring Universal Infusion Sets in the U.S. “The signing of this, our fourth distribution agreement in the U.S., is a key milestone achievement for our company,” D. Medical CEO Efri Argaman said in a statement, adding [...]

D. Medical gets CE Mark for insulin pump

D. Medical Industries (NASDAQ, TASE:DMED)  has received a CE Mark approval for its Spring Zone Insulin Delivery System, which replaces the first generation Spring ADI insulin pump. The proprietary Intellispring technology at the heart of the Spring Zone insulin pump results in performance advantages such as superior blockage and detachment detection, environmental (pressure and temperature) [...]

BioLineRx to develop Compugen’s novel peptide drug candidates

BioLineRx (NASDAQ, TASE:BLRX) and Compugen (NASDAQ:CGEN) have entered into a collaboration agreement to develop and commercialize mutually selected Compugen-discovered drug candidates for the treatment of various diseases, ranging from acute and chronic inflammatory diseases through cardiac diseases, retinopathy and cancer. Under the accord, Compugen will provide promising drug candidates, primarily peptides, which were identified using [...]

BioLineRx posts positive Phase 1a results in neuropathic pain

Final results of a Phase 1a study of BioLineRx’s (NASDAQ, TASE:BLRX) BL-1021 small molecule for neuropathic pain demonstrated that a single administration of BL-1021 in the dose range examined was safe and well tolerated, with no significant changes in vital signs, ECG or laboratory safety parameters at any dose when compared either to baseline measurements [...]

ThinkEquity starts Synta Pharma at buy

ThinkEquity has initiated coverage of Synta Pharmaceuticals (NASDAQ:SNTA) with a “buy” rating and 12-month price target of $6, predicting that ganetespib, Synta’s lead Hsp90 inhibitor, will “potentially demonstrate efficacy in a subset of lung cancer and can likely generate peak sales of approximately $450 million to $500 million, if approved.” The stock closed at $3.55 [...]

Rodman starts Celsion at market outperform

Rodman & Renshaw has initiated coverage of Celsion (NASDAQ:CLSN) with a “market outperform/speculative risk” rating and a target price of $6, based on a discounted revenues and earnings per share valuation methodology. The stock closed at $2.75 on Tuesday. “With approximately $25 million in cash pro forma, and an enterprise value of $47 million, we [...]

Roth ups AtriCure target to $15

Roth Capital Partners has raised its target price on AtriCure (NASDAQ:ATRC) to $15 from $13.50, heading into the company’s FDA advisory panel meeting. The stock was quoted at $11.80 Monday afternoon. “While FDA panel votes are difficult to predict, we view AtriCure’s risk-reward as positive and believe a positive recommendation would have major strategic implications [...]

Canaccord Genuity conference top picks

Canaccord Genuity has issued a report of its top picks – two value ideas and four growth ideas – coming out of its 31st annual Global Growth conference held last week in Boston. “While the overall equities markets’ direction may be a source of uncertainty in the near-term, we found our companies steadfastly holding to [...]

Next Page »